Q: I hold the above 7 stocks in my RRIF. I have to sell part of one of them soon.
Ignoring sector balance; I am concerned with maximizing long term growth whether it be capital gains, dividends or interest. So I would like to sell the one with the poorest prospects for gains over the next 2-3 years.
I should also note that my largest holding,NVDA, is over 7% of my entire investment holdings. This is a level where I would normally start to trim a bit but it has been on such a tear that I have been reluctant to trim it. And I note that you are still keen on it as a growth stock.
So I am comfortable to leave it alone if you agree.
Which would you suggest be sold?
Thank you
Q: I would appreciate your outlook for CHKP. I thought that the last qtr was decent with revenue, EPS, and earnings up somewhat. Nevertheless the share price seems stagnant since July. The P/E is quite low for this industry which suggests that the market is not expecting much growth. I was expecting that the "working from home" and "virtual learning" phenomena would be tailwinds. Since the company doesn't pay a dividend, if the price isn't going to grow, I should move on.
I look forward to your thoughts.
Thanks
Ian
Q: If you plan to buy U.S. securities, I was told you should set up a U.S. trading account. Is there an advantage to this? If you transfer Canadian dollars into this account and then eventually sell the stock, i am aware that you have to figure out the "cost" in canadian dollars on the day you purchased and also "cost" in canadian dollars the day you sell it for tax purposes.
thank you
Margaret
Q: Would like some recommendations for both Canadian and US large cap stocks where capital appreciation is more important Than any degree of dividend. Could you recommend five for each country? Feel free to charge more than one question. Thank you, Bill
Q: Hi Peter,
My rationale for buying Becton Dickinson (joint replacements) still makes sense to me, and I understand that these types of surgeries are down now, but looking forward should surge. That said, it has performed very poorly over recent months and Stryker, which I understand to be a similar company, has done quite well. Can you explain the divergence? Would you suggest I hang onto (or even add to BDX) or should I admit that I picked the wrong stock and would be better switching to SYK. Thank you!
Q: Good morning 5i: I would like to have a small position in a US vaccine company. Both Moderna and Novavax had great run-ups these past few days. Should I wait for pull back or jump in? And which one would you prefer? Thanks so much.
Q: Hi team,
What do you think of this recently created ETF ?
It looks good to cover Covid-19 vaccines, but also other epidemics diseases after the present pandemic. Any better ideas ?
Q: Could you comment on the short position by Citron? Would you buy more, sell or hold if one has already invested in PLTR shares, assuming the money is not needed any time soon?